GROSS LAW FIRM

Fennec Pharmaceuticals Inc. Loss Submission Form

The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Middle District of North Carolina on behalf of shareholders of Fennec Pharmaceuticals Inc. who purchased shares between February 11, 2020 and August 10, 2020.

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company’s sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.

Shareholders have until November 2, 2020 to request that the court appoint them lead plaintiff.

To receive more information, please fill out the form.

The Gross Law Firm does not share your information with others. There is no other or obligation for you to submit.

Name

Email

Physical Address

Phone Number

Shares Owned

Purchase Date

Loss

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.